Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Clinical trial NCT06463587 · RECRUITING
Trial details
- NCT number
- NCT06463587
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-25
- Primary completion
- 2028-08-23
- Enrollment
- 264
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.